To the Editor: Jänne et al. (July 14 issue)1 report the results of a phase 2 study of adagrasib involving patients with KRASG12C-mutated non–small-cell lung cancer (NSCLC). In a post hoc evaluation for intracranial response, the authors highlight a confirmed objective response rate of 33.3% among 33 patients. These patients had previously treated, stable central nervous system (CNS) metastases, and 81.8% of the patients had received radiation therapy before adagrasib treatment (59% within 3 months before study entry and 37% at least 6 months before study entry). CNS target lesions were evaluated in only 13 patients, 9 of whom (69%) . . .